drugset / Trial / NCT01081938
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary Objective: 1- Proportion of patients with mean daily glycemia \<140mg/dL during the period of 7 days of treatment with glargine plus supplemental glulisine versus patients with glulisine sliding scale. Secondary Objective: 1. Incidence of moderate hyperglycemia (\>140mg/dL) during the treatment period. 2. Incidence of hypoglycemia (\<60mg/dL and \< 40mg/dL) during the treatment period. 3. Incidence of severe hyperglycemia (\>400mg/dL) during the treatment period. 4. Total dose of insulin and correction dose in each group.
Timeline
- Start
- 2010-02
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin glulisine | Protein / enzyme biologic | — | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |